ʻO Trazhenta kahi lāʻau lapaʻau hypoglycemic i aʻo ʻia no ka hoʻohana kūloko. Hoʻohana ʻia ka huahana i ke ʻano o nā pōʻai, nā papa ʻulaʻula kukui me nā ʻaoʻao convex a me nā kihi beveled. Ma kekahi ʻaoʻao o ka papa papa, ʻo ia ka logo ʻoihana, a ma kekahi, ke hōʻailona D5.
ʻO ka mea hana nui o ka lāʻau ʻo 5 mg o linagliptin, nā mea kōkua o ka lāʻau lapaʻau ka huʻai palaoa, mannitol, magnesium stearate, copovidone, pregelatinized starch. Oe ke kuai i ka lāʻau lapaʻau i loko o alumini blam o 7 papa i kēlā me kēia.
Hoʻomaopopo ʻia ka lāʻau lapaʻau no ka hoʻohana me ka diabetes mellitus type 2, e lilo ia i mea ala i kekahi o nā lāʻau kūpono loa inā inā, e kū'ē ana i ke ʻano o ke ʻano kino kino a me ka ʻai, ʻaʻole hiki ke mālama i ke kōpaʻa koko ma ke ʻano maʻamau.
Pono ke ʻano o ka lāʻau lapaʻau inā loaʻa ka mōneka i ka mōʻaukala o ka pilikia ʻole, ka contformicated ʻo Metformin a i ʻole hoʻi i ʻae ke kanaka i kēia lāʻau. Hiki ke hoʻohana pū ʻia me Trazent me:
- kumuliiu aoli;
- Thiazolidine;
- Metformin.
Pēlā pono e pono ai ka lāʻau lapaʻau inā pono nā lāʻau lapaʻau me kēia mau lāʻau e hoʻomaikaʻi i ka pono o ka mea maʻi.
ʻO Trazenta, ʻo ke kumukūʻai no nā papa 30 o 5 mg e pili ana i 1,500 rubles, hiki iā ʻoe ke kūʻai iā ia i loko o ka hale kūʻai hoʻomehana a me ka lāʻau lapaʻau pūnaewele. Ua hoʻokomo ʻia ka lāʻau lapaʻau ma ka radar (hoʻopaʻa inoa i nā lāʻau lapaʻau). Ka hoʻohālikelike o ka lāʻau lapaʻau: Nesina, Onglisa, Yanuviya, Galvus, Komboglisa, nā analogue taugehana ʻē aʻe i kēia manawa.
Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau
Ke hōʻike nei nā ʻōkuhi e pono e mālama i ka lāʻau i ka wā hapai, ke ʻano o ka maʻi diabetes, 1 ka wā e hoʻolako nei, nā keiki ma lalo o ka makahiki 18 makahiki, me ka hoʻonui ʻia ʻana o kekahi mau mea o ka lāʻau, ka ketoacidosis i kumu o ka maʻi mellitus.
ʻO ka maʻa maʻamau no ka mea maʻi maʻi he 5 mg, pono ʻoe e mālama i ka hoʻomaʻamaʻa ʻekolu mau manawa i ka lā. Ke lawe ʻia nei ka lāʻau lapaʻau me Metformin, ʻaʻole loli i kona ʻano. ʻO ka lāʻau lapaʻau no nā poʻe maʻi me nā hana pūlohelohe pilikia ʻole ka mea pono e hoʻoponopono.
I ka wā e noiʻi ana i ka pharmacokinetics, ua ʻike ʻia me nā pilikia o ka ate ua hiki ke hoʻololi i ka nui o nā lāʻau o ka lāʻau, eia naʻe, i kēia manawa, ʻaʻohe ʻike paʻa me ka hoʻohana ʻana o ia lāʻau lapaʻau i ka maʻi maʻi maʻi maʻi.
ʻAʻohe mea e pono e hoʻoponopono i ka maʻi maʻi no nā maʻi maʻi, akā:
- aka hoi, aole ia o ka noonooia no na mea maʻi ma mua o 80 e lawe i ka laau, no ka mea, aole he ike kulana;
- no laila ʻaʻole ia i hoʻokumu maoli i ka palekana o ka mālama ʻana i nā keiki a me nā ʻōpio
Ke lawe nei ka maʻi maʻi maʻi i ka hala o Trazent a me ka hala ʻole o ka make i ka nui o ka maʻi, pono ia e lawe i ka pōʻai hou i ka manawa hiki loa ʻia, akā ʻaʻole hiki ke kāhea ʻia kona nui. Lawe ʻia ka lāʻau lapaʻau i kēlā me kēia manawa, me ka ʻole o ka meaʻai.
Hiki i ka hoʻomaʻamaʻa e like me nā ʻano like ʻole. Hoʻohana ʻia nā papa e like me ka monotherapy no nā maʻi maʻi me ka hiki ʻole o ka mālama glycemic kū'ē i kahi kūlana o ke koena o ka momona diabetes, a me ke ʻano kino, inā ʻaʻole ʻae i ke kanaka i ka Metformin, nā lāʻau like.
E lilo ka lāʻau lapaʻau i ka ʻāpana ʻelua o ka mālama ʻana i ka Metformin, thiazolidinediones, sulfonylurea derivatives i ka lilo ʻole ʻana o nā hopena monotherapy i kapa ʻia nā lāʻau lapaʻau, ka nele o ka hana kino a me ka meaʻai.
Hoʻohana ʻia ka lāʻau lapaʻau e like me kahi lāʻau hoʻohui ʻekolu mau pūnaehana me nā mea waiwai o Metformin. Kuhi aku nō hoʻi ke kauka i ka lāʻau lapaʻau me:
- inikua insulin;
- Pioglitazone;
- ololilurea derivatives.
Ma hope o ka noi ʻana iā 5 mg o ka lāʻau i loko, e hoʻomaka nā mea ikaika, e hōʻea i ka pae kiʻekiʻe ma hope o 1,5 mau hola. E emi ka paʻa ʻana e like me kahi hoʻolālā hana ʻekolu, ʻoi aku ka nui o ka hapa ʻoi aku ma mua o 100 mau hola, i mea e paʻa ai ka paʻa ʻana o ka linagliptin.
ʻO ka hapalua ola maikaʻi mai ke kino ma hope o ka hoʻokele mau ʻana o ka lāʻau lapaʻau he mau hola 12.
Ma hope o ka hoʻohana hoʻokahi ʻana i ka lāʻau, ʻike pono ka paʻa ʻana o ka waiwai ma hope o ke kolu o ka pau ʻana.
Nā hihia o ka overdose, nā hewa ʻino o ke kino
Hōʻike nā hōʻike noiʻi lāʻau lapaʻau i ka hoʻohana hoʻokahi o 600 mg o ka lāʻau lapaʻau ʻaʻole e hoʻonā i nā hōʻailona overdose a ʻaʻole hōʻino i ka olakino o ka maʻi maʻi. ʻAʻohe ʻike e pili ana i nā hihia overdose. Eia naʻe, no ka palekana, i ka wā e hoʻohana ai i ka nui o ka lāʻau lapaʻau, pono nui e hūnā i ka ʻōpū ma ka holoi ʻana a i ka hoʻoulu ʻana paha.
E kamaʻilio pololei i kahi kauka a kāhea aku i kahi kime ambulance. Eia paha kekahi hewa ʻae i ke olakino, pono ia e kuhikuhi i ke ʻano kūpono.
ʻO kekahi mea ʻē aʻe nā hopena ʻino o ke kino, ʻo ka nui o kēlā mau hoʻohālike e like me ka nui o nā hopena maikaʻiʻole e like me ka lawe ʻana i kahi placebo. No laila, hoʻomaka ka mea maʻi: kahi hana maʻi i ka pancreas, ka hōʻopa ʻana i ka hōʻoki ʻana, ka nasopharyngitis, hoʻonui ʻia i ka nānā ʻana i kekahi mau mea, hypertriglyceridemia.
Pono ʻoe e ʻike hiki i ke ʻano ikaika o ka lāʻau lapaʻau ke hiki i ka huki ʻana, no laila:
- ʻoi aku ka maikaʻi e pale i ka hoʻokele a me nā mīkini paʻakikī;
- Hōʻalo i ka hana kino kino.
ʻO nā hopena ʻino e kū nei i ka wā hele ma ke ʻano o ka maʻi me Trazent me ka derogatives sulfonylurea a me Metformin.
Ke hana pinepine ʻia ka launa pū me nā mea o ka linagliptin a i ka pioglitazone paha, hoʻomaka pinepine ka maʻi maʻi maʻi maʻi, pancreatitis, hypersensitivity o ka ʻōnaehana pale.
Nā ʻōlelo kikoʻī
ʻAʻole i kuhikuhi ʻia ka lāʻau lapaʻau no nā wahine hāpai, ʻo kona hopena ma ke kino wahine i ka wā hānau keiki ʻaʻole i aʻo ʻia a hiki i kēia lā. Eia naʻe, ʻaʻole i hōʻike nā pilikia lapaʻau i nā holoholona i nā hopena maikaʻi ʻole e pili ana i ka hana hoʻoulu. ʻAʻole i hoʻokō ʻia nā hoʻokolohua ma ka hiki i ka wahine ke hoʻohilahila, ʻaʻole i hōʻike ʻia ka hoʻokolohua ma nā holoholona.
ʻO nā ʻikepili i loaʻa i ka wā ʻo ka ʻoihana pharmacodynamic i luna o nā holoholona e hōʻike ana i ka hiki ʻana o ka lāʻau i loko o ka waiū umauma. No kēia kumu, ʻaʻole i haʻalele ʻia ka hopena o ka lāʻau lapaʻau ma ke keiki. I kekahi mau hihia, hoʻomau nā kauka i ka hoʻokuʻu ʻana o ka lactation i loko o ka wahine, inā aia ke koi wikiwiki e koho iā ia ʻo Trazhenta pololei.
ʻO nā ʻōlelo aʻoaʻo Trazenta no ka hoʻohana ʻana he pono ke mālama i ka lāʻau lapaʻau i ka mahana o nā mea kiʻekiʻe ʻole aʻe ma mua o 25 tikelika ma kahi wahiʻeleʻele, kahi mamao mai nā keiki. ʻO 2.5 mau makahiki kahi ola.
ʻAʻole kuhikuhi nā Endocrinologists i nā lāʻau lapaʻau i nā mea maʻi:
- me ka maʻi ʻōpala 1;
- me ka ketoacidosis maʻi maʻi maʻi.
Hiki i ka hoʻomohala maʻi hoʻomohala i ka hypoglycemia, ke kumu e pili ai me ka launa pū me ka sulfonylureas.
ʻAʻohe ʻikepili i ka pili o ka lāʻau me ka insulin; nā mea maʻi me ka maʻi ʻole o ka maʻi hakahaka i kuhikuhi ʻia i ka mālama ʻana me nā lāʻau ʻē aʻe e hoʻomaʻamaʻa i ka pae o ka glycemia. He maikaʻi wale nā loiloi Trazenta.
I ka wā e hoʻohana pono ai me ka lāʻau lapaʻau, e hoʻonui ʻo Ritonavir i ka linagliptin e pili ana i ka 2-3 mau manawa, ke kumu lau ʻole (ʻoi aku ka manawa o ka 1% o ka laʻau lapaʻau), a e hoʻonui 5 mau manawa ma hope o kēia hoʻohui o nā lāʻau lapaʻau. ʻAʻole i manaʻo ʻia nā loli i ka pharmacokinetics he kumu koʻikoʻi koʻikoʻi, no kēia kumu ʻaʻole i manaʻo nui ʻia ka launa pū me nā mea ʻē aʻe.
Ke mālama nei me Rifampicin, e emi ana ka lāʻau o ka pharmacokinetics o nā lāʻau ʻelua mai 39 a 43%, he hōʻemi i kahi hana basal i pale ʻia e 30%. Mālama ʻia ka pono o ka mālama ʻana, akā ʻaʻole kēia i mea piha.
I ka wā o ka noi o Trazhenty me Digoxin, ʻaʻole i kū ka hopena o ke kau ʻana, ʻoiai inā he hoʻohana like like ʻole:
- pinepine;
- i nā ʻano waihona ʻokoʻa.
Ke hoʻohana hou nei i ka lāʻau lapaʻau ma loko o kahi ala o 5 mg / lā ʻaʻole hiki ke hoʻololi i ka pharmacokinetics o Warfarin. Inā hoʻohana ʻia ʻo Simvastatin a me ka nui o ka dosis linagliptin e hoʻohana pinepine ʻia, kahi hopena ma ka pharmacokinetics o ka lāʻau mua. He ʻano maʻamau kēia kūlana; ʻaʻole pono ke hoʻoponopono ʻia o nā ʻano loiloi. Ma hope o ka mālama kino ʻana me Trazenta i ka nui o ka nui a me Simvastatin 40 mg, ua hoʻonui ʻia ka hana o kēia e 34%, i loko o ke koko ma ka 10%.
Ke lawe aku nei ka maʻi maʻi o ka lua o nā lā i ka mea e hoʻohālikelike ai i ka wai o ka maʻi i ka wā e mālama ai iā Trazenta, ʻaʻohe ʻano nui a koʻikoʻi i loli i ka pharmacokinetics o ia mau lāʻau.
Hōʻike loiloi
Hoʻololi ka DPP-4 (ʻo ka lāʻau ka hui i kēia ʻāpana) ʻaʻole i ka hopena wale nō me ka hopena o ka hoʻohaʻahaʻa i ke kō, akā hoʻi i ka hoʻonui ʻana o ka palekana, no ka mea hiki ʻole iā lākou ke kiʻi i ka hoʻonui nui o ke kino o ka maʻi maʻi a me kahi kūlana hypoglycemic. Manaʻo ʻia nā lāʻau o kēia pūʻulu e ʻoi aku ka maikaʻi a me ka hoʻohiki ʻana i ka mālama ʻana i ka maʻi type 2 i nā keiki a me nā pākeke.
Ua hōʻoia ʻia ka hopena o ka lapaʻau e nā haʻawina ʻepekema he pono, he mea pono ia e hoʻomaka i kahi papa o ka lapaʻau ʻana i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe. Ke hele nei i kahi predisposition e hoʻokaʻawale i ke kūpaʻa o ka glucose a me kona hoʻokaʻawale ʻana, kahi i hōʻike ʻia nā hali no ka sulfonylureas.
I kekahi manawa ua hoʻāpono ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau i ke ala no ka monotherapy me ka pale ʻana o ke kino i ka insulin hormone a me ke kaumaha. Aia ma hope o 3 mau mahina o ka lapaʻau, ua ʻike ʻia kahi emi nui o ke ana ʻana o nā paona.
Loaʻa ka helu nui o nā loiloi mai kēlā mau mea maʻi i hoʻohana i ka 5 mg o ka lāʻau ma ke ʻano he lāʻau paʻakikī. I ka ʻike ʻana i kēia, ʻoi aku ka paʻakikī o ka loiloi ʻana i hoʻopaʻa ʻia iā Trazhent e ia:
- kūlohelohe;
- palekana.
Eia naʻe, aneane nā maʻi āpau e maopopo ka lāʻau lapaʻau kēia i kōkua iā lākou e nalo i ke kaumaha.
ʻOiai kekahi o nā kauā ʻana ma ka hoʻohana ʻana iā Trazent, ua kuhikuhi ʻia i ka poʻe maʻi maʻi o ka lua o nā ʻano o kēlā me kēia makahiki, ʻo ke ʻano hoʻi o nā lunakahiko, e loaʻa ana i nā maʻi o nā kolo, ate, a i ka naʻau. ʻO ka hopena maʻamau e hōʻike ai i kēia maʻi ʻo ka nasopharyngitis.
Hāʻawi ʻia ka ʻikepili e pili ana i ka hana a DPP-4 inhibitors i ke wikiō ma kēia ʻatikala.
